Malignant Cervical Neoplasm — Trials

Malignant Cervical Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 506
Recruiting: 280
Ph III recruiting: 34
Growth YoY: −11.9%
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 22.7%
Trials / 1,000 deaths: 121.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (181)

clinicaltrialsPublishedShowing 51–61 of 61 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00626561	Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix	terminated	Phase 2	4	M.D. Anderson Cancer CenterOTHER	1	Jul 7, 2014	clinicaltrials
NCT00138151	Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer	terminated	Phase 2	33	University of Medicine and Dentistry of New JerseyOTHER	1	Nov 20, 2013	clinicaltrials